SIRT5 and central nervous system cancer: Our analysis revealed that high SIRT5 expression was associated with improved patient outcomes, including a longer duration of disease-specific survival (DSS), overall survival (OS), progression-free interval (PFI), and progression-free survival (PFS) in Grade 2–4 glioma patients (Figure 1A).